Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases

An R. Van Rompay a, Magnus Johansson b, Anna Karlsson b,*

a Department of Nephrology-Hypertension, University of Antwerp, 2610 Antwerp, Belgium
b Division of Clinical Virology, Huddinge University Hospital, F68, Karolinska Institute, S141 86 Stockholm, Sweden

Abstract

Structural analogues of nucleosides, nucleoside analogues (NA), are used in the treatment of cancer and viral infections. Antiviral NAs inhibit replication of the viral genome, whereas anticancer NAs inhibit cellular DNA replication and repair. NAs are inactive prodrugs that are dependent on intracellular phosphorylation to their pharmacologically active triphosphate form. The deoxyribonucleoside kinases (dNK) and ribonucleoside kinases (rNK) catalyze the first phosphorylation step, converting deoxyribonucleosides and ribonucleosides to their corresponding monophosphate form. The dNKs have been studied intensively, whereas the rNKs have not been as thoroughly investigated. This overview is focused on the substrate specificity, tissue distribution, and subcellular location of the mammalian dNKs and rNKs and their role in the activation of NAs.

© 2003 Elsevier Inc. All rights reserved.

Keywords: Antiviral therapy; Anticancer therapy; Chemotherapy; Nucleoside analogue; Deoxyribonucleoside kinase; Ribonucleoside kinase

Abbreviations: ADK, adenosine kinase; AIDS, acquired immunodeficiency syndrome; AraC, 1-beta-D-arabinofuranosylcytosine (Cytarabine); AraG, 9-beta-D-arabinofuranosylguanine (Nelarabine); AZT, 3'-azido-2',3'-dideoxythymidine (Zidovudine); CAFdA, 2-chloro-2',2'-difluorodeoxycytidine (Gemcitabine); dCK, deoxycytidine kinase; ddC, 2',3'-dideoxythymidine (Zalcitabine); ddT, 2',3'-dideoxycytidine (Didanosine); dGK, deoxyguanosine kinase; dFdC, 2',2'-difluorodeoxycytidine (Gemcitabine); dNK, deoxyribonucleoside kinase; d4T, 2',3'-didehydro-3'-deoxythymidine (Stavudine); F-AraA, 2-fluoro-9-beta-D-arabinofuranosyladenine (Fludarabine); FDA, Food and Drug Administration; FIAU, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil (Fialuridine); HBV, hepatitis B virus; mtDNA, mitochondrial DNA; HIV, human immunodeficiency virus; NA, nucleoside analogue; NDPK, nucleoside diphosphate kinase; NMPK, nucleoside monophosphate kinase; 5'-NT, 5'-nucleotidase; rNK, ribonucleoside kinase; RR, ribonucleotide reductase; RT, reverse transcriptase; TK1, thymidine kinase 1; TK2, thymidine kinase 2; UCK1, uridine-cytidine kinase 1; UCK2, uridine-cytidine kinase 2; 3TC, 2'-deoxy-3'-thiacytidine (Lamivudine).

Contents

1. Introduction ............................................ 120
2. Deoxyribonucleotide and ribonucleotide synthesis in mammalian cells ......................................... 120
3. The salvage pathways of deoxyribonucleotide and ribonucleotide metabolism .............................. 122
3.1. Substrate specificity ..................................... 122
3.2. Genetics ............................................. 123
3.2.1. Sequences ........................................... 123
3.2.2. Chromosomal location .............................. 123
3.3. Subcellular location .................................... 123
3.4. Cell cycle regulation and tissue distribution .......... 124

* Corresponding author. Tel.: +46-8-585879352; fax: +46-8-58587933.
E-mail address: anna.karlsson@mbb.ki.se (A. Karlsson).

0163-7258/$ – see front matter © 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.pharmthera.2003.07.001
1. Introduction

Deoxyribonucleotides and ribonucleotides are the building blocks of DNA and RNA, respectively. Both nucleotides are built up by a nitrogen ring-structured base, a pentose sugar (deoxyribose or ribose), and a phosphate group. DNA is replicated by enzymes known as DNA polymerases. The human DNA polymerases α, β, δ, and ε are located in the cell nucleus and these enzymes replicate and repair nuclear DNA (Zannis-Hadjipoulus & Price, 1999; Hubscher et al., 2000). Mitochondrial DNA (mtDNA) replication is catalyzed by DNA polymerase γ (Taanman, 1999). These enzymes use single-stranded DNA as templates on which they catalyze the synthesis of the complementary strand from deoxyribonucleoside triphosphates (dATP, dCTP, dGTP, and dTTP). The nucleotides are added to the free 3′-OH group of the base-paired polynucleotide so that DNA chains are extended in the 5′ → 3′ direction (Fig. 1).

The accuracy of DNA replication is fundamental for the genetic stability of the cell. From bacteria to higher eukaryotes, error frequencies range from $10^{-3}$ to $>10^{-6}$ per base replication (Timsit, 1999; Kunkel & Bebenek, 2000). Although errors in the DNA synthesis play a role in aging and diseases like cancer, spontaneous mutations also provide the opportunity for genetic variation and are a primary basis for the evolution. A high fidelity of DNA replication is required to maintain the mammalian genome of $3 \times 10^9$ bp and is dependent on a balanced supply of the 4 deoxyribonucleotides (Reichard, 1988). Inhibition of deoxyribonucleotide synthesis results in mutagenic changes, cell growth arrest, or cell death. Two examples of compounds that interfere with the synthesis of deoxyribonucleotides are hydroxyurea that inhibits ribonucleotide reductase (RR) and methotrexate that inhibits dihydrofolate reductase, thymidylate synthase (TS), and also the purine nucleotide de novo pathway (Fig. 2B). Inhibition of the enzymes results in deoxyribonucleotide pool imbalances and thus impaired DNA replication. Another way to interfere with DNA synthesis is by structurally modified nucleosides (i.e., nucleoside analogues [NA]). NAs that lack the 3′-OH group are incorporated into DNA and act as chain terminators because no new deoxyribonucleotide can be attached to the growing DNA strand (Fig. 1). NAs with an intact 3′-OH group are not absolute chain terminators, but there is evidence that they are incorporated into DNA and then severely impair chain elongation (Tan et al., 1999).

2. Deoxyribonucleotide and ribonucleotide synthesis in mammalian cells

Deoxyribonucleotides and ribonucleotides have to be synthesized within the cells because there are no carrier proteins for them in the cell membrane and the negatively

Fig. 1. Deoxyribonucleoside triphosphates are the substrates of DNA polymerase catalyzed replication of DNA. The deoxyribonucleotides are added to the free 3′-OH group of the base-paired polynucleotide so that DNA chains are extended in the 5′ → 3′ direction.
charged phosphate groups prevent diffusion across the membrane. There are 2 pathways for both deoxyribonucleotide and ribonucleotide synthesis, called the de novo pathway and the salvage pathway (Reichard, 1988). Via the de novo ribonucleotide pathway, ribonucleotides are synthesized from small molecules (e.g., amino acids, ribose-5-phosphate, and CO$_2$) to ribonucleoside monophosphates and then further phosphorylated (Fig. 2B). The 2'-OH group of the ribonucleoside diphosphate can also be reduced to the corresponding 2'-deoxyribonucleoside diphosphate via the de novo deoxyribonucleotide pathway. This irreversible reaction is catalyzed by RR (Reichard, 1988; Greenberg & Hilfinger, 1996; Burton et al., 2003). In proliferating cells, the de novo deoxyribonucleotide synthesis is the main source for nuclear DNA replication (Wright et al., 1990). Deoxyribonucleotides synthesized in the salvage pathway are believed to be important for DNA repair (Xu et al., 1995). The salvage deoxyribonucleotide pathway is derived from deoxyribonucleosides and catalyzed by deoxyribonucleoside kinases (dNK), nucleoside monophosphate kinases (NMPK), and nucleoside diphosphate kinases (NDPK) (Fig. 2B). In addition, there are 2 salvage pathways for ribonucleotides. The first is from free bases and then further phosphorylated via direct sugar phosphate transfer, and the second salvage ribonucleotide pathway is from ribonucleosides with further phosphorylation to their triphosphate form (Fig. 2A and B) (Kornberg & Baker, 1992). Ribonucleosides and deoxyribonucleosides are imported into the cells by nucleoside transport proteins that facilitate diffusion or replication (Wright et al., 1990). Deoxyribonucleotides synthesized in the salvage pathway are believed to be important for DNA repair (Xu et al., 1995). The salvage deoxyribonucleotide pathway is derived from deoxyribonucleosides and catalyzed by deoxyribonucleoside kinases (dNK), nucleoside monophosphate kinases (NMPK), and nucleoside diphosphate kinases (NDPK) (Fig. 2B). In addition, there are 2 salvage pathways for ribonucleotides. The first is from free bases and then further phosphorylated via direct sugar phosphate transfer, and the second salvage ribonucleotide pathway is from ribonucleosides with further phosphorylation to their triphosphate form (Fig. 2A and B) (Kornberg & Baker, 1992). Ribonucleosides and deoxyribonucleosides are imported into the cells by nucleoside transport proteins that facilitate diffusion or replication (Wright et al., 1990). Deoxyribonucleotides synthesized in the salvage pathway are believed to be important for DNA repair (Xu et al., 1995). The salvage deoxyribonucleotide pathway is derived from deoxyribonucleosides and catalyzed by deoxyribonucleoside kinases (dNK), nucleoside monophosphate kinases (NMPK), and nucleoside diphosphate kinases (NDPK) (Fig. 2B). In addition, there are 2 salvage pathways for ribonucleotides. The first is from free bases and then further phosphorylated via direct sugar phosphate transfer, and the second salvage ribonucleotide pathway is from ribonucleosides with further phosphorylation to their triphosphate form (Fig. 2A and B) (Kornberg & Baker, 1992). Ribonucleosides and deoxyribonucleosides are imported into the cells by nucleoside transport proteins that facilitate diffusion or replication (Wright et al., 1990). Deoxyribonucleotides synthesized in the salvage pathway are believed to be important for DNA repair (Xu et al., 1995). The salvage deoxyribonucleotide pathway is derived from deoxyribonucleosides and catalyzed by deoxyribonucleoside kinases (dNK), nucleoside monophosphate kinases (NMPK), and nucleoside diphosphate kinases (NDPK) (Fig. 2B). In addition, there are 2 salvage pathways for ribonucleotides. The first is from free bases and then further phosphorylated via direct sugar phosphate transfer, and the second salvage ribonucleotide pathway is from ribonucleosides with further phosphorylation to their triphosphate form (Fig. 2A and B) (Kornberg & Baker, 1992). Ribonucleosides and deoxyribonucleosides are imported into the cells by nucleoside transport proteins that facilitate diffusion or
actively transport nucleosides across the membrane (Cass et al., 1999). The phosphorylation from ribonucleosides to their ribonucleoside monophosphates is catalyzed by the ribonucleoside kinases (rNK), while the phosphorylation reaction of deoxyribonucleosides is catalyzed by dNK (Fig. 2B). Both dNK and rNK phosphorylation reactions are irreversible. However, the monophosphates can be dephosphorylated to their nucleosides by 5'-nucleotidases (5'-NT) (Reichard, 1988; Rampazzo et al., 2000). Conversion of ribonucleoside monophosphates and deoxyribonucleoside monophosphates to their triphosphate forms occurs in 2 subsequent reversible phosphotransferase reactions catalyzed by the NMPKs and the NDPKs. There are 4 groups of NMPKs in human cells: a dTMP kinase (dTMPK), a UMP-CMP kinase (UMP-CMPK), 5 isozymes of adenylyl kinase (AK), and several guanylate kinases (GUK) (Van Rompay et al., 2000). The human NDPK family comprises at least 8 isozymes (Lacombe et al., 2000).

We are interested in enzymes involved in the activation of NAs. The NAs are phosphorylated, via ribonucleotide or deoxyribonucleotide salvage pathways, to their corresponding triphosphates. The initial phosphorylation step by dNKs is in most cases the rate-limiting step in the formation of dNTPs or NA-TPs and has been studied carefully (Arner & Eriksson, 1995; Johansson & Eriksson, 1996; Johansson et al., 1999; Tan et al., 1999; Galmarini et al., 2001, 2002); however, less is known about rNKs. Both will be the focus of this review. To reconstitute the metabolic pathways of activation and characterize all phosphorylation steps is important for the development and rational use of these compounds in antiviral and anticancer therapy.

3. The salvage pathways of deoxyribonucleotide and ribonucleotide metabolism

The deoxyribonucleosides and ribonucleosides are imported into cells by nucleoside transporters. The deoxyribonucleosides/ribonucleosides are then phosphorylated to their triphosphate forms in 3 subsequent phosphorylation steps that are catalyzed by dNKs/rNKs, NMPKs, and NDPKs.

3.1. Substrate specificity

In human cells, there are 4 dNKs: thymidine kinase 1 (TK1), thymidine kinase 2 (TK2), deoxycytidine kinase (dCK), and deoxyguanosine kinase (dGK) (Bohman & Eriksson, 1990; Arner et al., 1992; Arner & Eriksson, 1995). The nomenclature of these dNKs is based on the preferred substrate of the enzyme, but they also accept other substrates (Table 1). TK1 phosphorylates dThd and dUrd (Munch-Petersen et al., 1991). TK1 is able to use most phosphate donors, but ATP shows the highest efficiency (Ellims & Van der Weyden, 1981). TK2 is a pyrimidine dNK and phosphorylates dThd, dUrd, and dCyd (Munch-Petersen et al., 1991). In addition to dCyd, dCK phosphorylates dAdo and dGuo (Surap & Friland, 1987; Usova & Eriksson, 2002). The enzyme can use several nucleotides as phosphate donors (Shewach et al., 1992), and UTP is suggested to be an important phosphate donor (White & Hines, 1987; Turk et al., 1999). dGK phosphorylates dGuo, dAdo, and dino (Gower et al., 1979; Wang et al., 1993). dGK can use several phosphate donors, but in vitro UTP is the preferred phosphate donor (Zhu et al., 1998a).

There are 3 known rNKs in human cells: adenosine kinase (ADK), uridine-cytidine kinase 1 (UCK1), and uridine-cytidine kinase 2 (UCK2) (Spychala et al., 1996; Van Rompay et al., 2001). The existence of a human guanosine kinase has so far not been reported. ADK catalyzes the phosphorylation of Ado to AMP (Table 1) (Spychala et al., 1996). ADK has also been implicated in the phosphorylation of dAdo in vivo (Ullman et al., 1978). Although purified ADK has >1000-fold higher K<sub>m</sub> for dAdo than for Ado (Hurley et al., 1985), studies with ADK-deficient cell lines demonstrated that it accounts for a significant part of total dAdo phosphorylation in lymphoblastoid cell lines (Carson et al., 1977; Ullman et al., 1978). TK1 might play a major role in the phosphorylation of dAdo at higher concentrations, whereas dCK plays a critical role at low concentrations (Verhoef et al., 1981; Hershfield et al., 1982). ATP and GTP have shown to be effective phosphate donors for ADK (Yamada et al., 1981). ADK is feedback regulated by its products AMP and ADP (Palella et al., 1980). UCK catalyzes the phosphorylation of Urd and Cyt to UMP and CMP (Table 1). The enzyme has first been observed by Canellakis (1957) in mammalian liver and by Reichard and Sköld (1957) in Ehrlich ascites tumor and was then shown to be present in other rapidly proliferating tissues (Reichard & Sköld, 1958; Sköld, 1960a). Purification and properties of tissue-purified UCK have been reviewed (Anderson, 1973; Cihak & Rada, 1976; Traut & Jones, 1996). Different investigators have observed multiple enzyme peaks or bands by chromatography, isoelectric focusing, or electrophoresis (Krystal & Webb, 1971; Krystal & Scholfield, 1973; Fulchignoni-Lataud et al., 1976; Greenberg et al., 1977; Ahmed & Welch, 1979; Absil et al., 1980; Ahmed & Baker, 1980; Dubinina et al., 1982; Fulchignoni-Lataud & Roux, 1984). Recently, 2 human UCKs, named UCK1 and UCK2, have been cloned (Koi-
Both enzymes efficiently phosphorylate the ribonucleosides Ur and Cyd, and UCK2 has a higher catalytic rate compared with UCK1. The enzymes do not phosphorylate deoxyribonucleosides or purine ribonucleosides (Van Rompay et al., 2001). The 2 recombinant UCKs resemble the tissue-purified UCKs in exhibiting a broad specificity with regard to the phosphate donor, including dNTPs but not UTP and CTP (Anderson & Brockman, 1964; Orenigo, 1969; Payne & Traut, 1982), and regulation by changes in quaternary structure caused by orthophosphate, ATP, and CTP (Payne & Traut, 1982; Ropp & Traut, 1998). ATP stabilizes the enzyme in the active tetrameric form, whereas UTP and CTP dissociate the enzyme to an inactive monomer (Payne & Traut, 1982; Cheng et al., 1986).

### 3.2. Genetics

#### 3.2.1. Sequences

The cDNAs of the 4 human dNKs have been cloned (Bradshaw, 1984; Chottiner et al., 1991; Johansson & Karlsson, 1996, 1997). Alignment of the predicted amino acid sequence of TK2 with the sequences of dCK and dGK show that they are ≈ 33% identical (Fig. 3A). TK1 is related to TKs from Escherichia coli and poxviruses and shows little sequence similarity with the other dNKs (Gentry, 1992; Eriksson & Wang, 1997). It is likely that all 4 human dNKs have originated from a common progenitor kinase. It is proposed that the first gene duplication generated the progenitor of the TK1-like kinases and the progenitor of the TK2-like and dCK/dGK-like kinases (Johansson et al., 1999; Knecht et al., 2002). To date, a crystal structure has been determined for dGK and recently for dCK (Johansson et al., 2001; Sabini et al., 2003). For TK1, TK2, dCK, and dGK, the coding region is distributed in 7, 10, 7, and 7 exons, respectively (Fig. 4).

Three cDNAs of the human rNKs have also been cloned. From human tissues, 2 different isoforms of human ADK have been cloned and sequenced (Spychala et al., 1996; McNally et al., 1997). The isoforms are similar in biochemical and functional properties but have a sequence variation in the 5’ end where the first 4 encoded residues of the short form are replaced by 21 residues in the long form (McNally et al., 1997). These 2 mRNA forms are postulated to arise from a single ADK gene by differential splicing (Spychala et al., 1996; McNally et al., 1997). So far, the significance of the 2 forms has not been elucidated. The ADKs show little sequence similarity to other mammalian rNKs. In contrast, 2 regions were identified with significant sequence identity to microbial ribokinases and fructokinases and a bacterial inosine/guanosine kinase (Spychala et al., 1996; Mathews et al., 1998). ADK is grouped with these carbohydrates and other purine kinases into the pfol family. The crystal structure of ADK has recently been solved from human ADK (Mathews et al., 1998) as well as from Toxoplasma gondii ADK (Cook et al., 2000; Schumacher et al., 2000). Structure-activity relationships have been examined for Chinese hamster ADK by making systematic deletions of the N-terminal and C-terminal ends (Maj et al., 2000). For human ADK, the coding region is distributed in 11 exons (Fig. 4).

The longest open reading frame of UCK1 encoded a 277-amino acid protein with a predicted mass of 31 kDa. UCK2 consists of 261 amino acids and has a predicted mass of 29 kDa (Van Rompay et al., 2001). Human UCK1 and UCK2 were 72% similar in amino acid sequence, and the enzymes were ≈ 37 and ≈ 28% similar to UCK of Caenorhabditis elegans and E. coli, respectively (Fig. 3B). For both human UCK1 and UCK2, the coding region is distributed in 7 exons (Fig. 4).

#### 3.2.2. Chromosomal location

From the human dNKs, human TK1 gene is localized to chromosome 17q25.2–17q25.3 (Kuo et al., 1996; Petty et al., 1996), TK2 to chromosome 16q22–16q23.1 (Johansson & Karlsson, 1996), dCK to chromosome 4q13.3–4q21.1 (Stegmann et al., 1993), and dGK to chromosome 2p13 (Johansson et al., 1996).

From the rNKs, human ADK gene has been assigned to the region 10q11–10q24 (Klobutcher et al., 1976; Francke & Thompson, 1979). The human UCK1 gene and the UCK2 gene were localized to chromosome 9q34.2 and 1q22–1q23.2, respectively (Van Rompay et al., 2001).

#### 3.3. Subcellular location

TK1 is a cytosolic enzyme and TK2 is a mitochondrial enzyme with a N-terminal mitochondrial import signal (Fig. 5 and Table 2) (Kit & Leung, 1974; Lee & Cheng, 1976; Wettin et al., 1999; Wang & Eriksson, 2000). In Fig. 5, TK2 green fluorescent protein (GFP) shows mainly a cytosolic fluorescence with a fluorescent border outlining the cell membrane (Johansson et al., 1997). This human TK2 is most likely an alternatively spliced cDNA isoform of human TK2 that lacks the N-terminal mitochondrial targeting sequence. The mitochondrial location of TK2 is supported by the fact that that full-length mouse TK2 has a mitochondrial location (Wettin et al., 1999; Wang & Eriksson, 2000) and that mtDNA depletion syndrome (MDS) has been linked to mutations in TK2 and dGK (Saada et al., 2001; Mancuso et al., 2002). The recombinant dCK has a nuclear import signal and dCK fused with GFP is located in the nucleus (Johansson et al., 1997), whereas the native dCK is reported to be located in the cytosol (Hatzis et al., 1998). The importance of the transport of dCK between subcellular compartments remains unclear. The N-terminal sequence of dGK contains a mitochondrial import signal and the enzyme is located in the mitochondrial matrix (Gower et al., 1979; Jüllig &
Eriksson, 2000). Surprisingly, dGK might be relocated to the cytosolic compartment during apoptosis (Jüllig & Eriksson, 2001).

ADK is reported to be a cytosolic enzyme (Table 2) (Andres & Fox, 1979). UCK activity, however, has been detected in nuclear, cytosolic, and microsomal fractions in different investigated cells and tissues (Durham & Ives, 1972; Cihak & Rada, 1976; Greenberg et al., 1977). Expression of UCK1 and UCK2 in fusion with GFP showed that UCK1-GFP was predominantly located in the nucleus, whereas UCK2-GFP was located in the cytosol (Fig. 5 and Table 2) (Van Rompay, 2001). The relevance of this finding is probably minimal because the nuclear membrane allows diffusion of small proteins and nucleotides between the cytosol and the nucleus.

3.4. Cell cycle regulation and tissue distribution

TK1 expression is regulated throughout the cell cycle, with transcriptional, translational, and post-translational
regulatory mechanisms. Both TK1 mRNA and protein rise near the G1/S boundary, peak in early S phase, and decline again in the G2 phase (Sherley & Kelly, 1988; He et al., 1996; Kim et al., 1997). The reason for such a meticulous control has not been fully elucidated, but several regulatory mechanisms have been proposed: (1) a 20-bp inverted CCAAT motif in the promoter of TK1, responsible for transcriptional activation of the TK1 gene; (2) post-transcriptional and post-translational mechanisms such as half-life of TK1 mRNA and TK1 protein that regulate TK1 activity; (3) a 40-amino acid sequence in the carboxyl terminus specific for degradation of TK1 at mitosis; (4)
the extent of phosphorylation of serine residues of the TK1 protein; (5) at the enzymatic level, an ATP-dependent reversible shift between a low and a high affinity form of TK1; and (6) a S phase-dependent mechanism on the transcription factor E2F, in complex with several other factors (Arné & Eriksson, 1995; Munch-Petersen et al., 1995). TK2, dCK, and dGK are expressed throughout the cell cycle. TK2 represents a rather small fraction of cellular TK levels, compared with TK1 activity, in proliferating cells. However, TK2 corresponds to the predominant fraction of TK activity in resting or terminally differentiated cells, where TK1 activity is virtually undetectable (Johansson & Karlsson, 1997). The TK2 activity in tissue extracts appears to be proportional to the cellular mitochondrial content rather than with the growth state of the cells (Arné et al., 1992). TK2 has been purified from many tissues such as spleen, liver, heart, and brain (Jansson et al., 1992). Northern blot analyses show TK2 mRNA species with a ubiquitous expression (Johansson & Karlsson, 1997; Wang et al., 1999), with the highest levels in liver, pancreas, muscle, and brain. dCK does not seem to be cell cycle regulated (Richel et al., 1990). dCK is expressed at low levels in most tissues, but high levels are present in lymphoid tissues with particularly high levels in immature T-lymphoblasts (Arné et al., 1992). Northern blot analyses show TK2 mRNA species with a ubiquitous expression (Johansson & Karlsson, 1997; Wang et al., 1999), with the highest levels in liver, pancreas, muscle, and brain. dCK does not seem to be cell cycle regulated (Richel et al., 1990). dCK is expressed at low levels in most tissues, but high levels are present in lymphoid tissues with particularly high levels in immature T-lymphoblasts (Arné et al., 1992). Northern blot analyses showed that dCK mRNA had the highest levels in thymus, skeletal muscle, fetal liver, bone marrow, and brain (Johansson & Karlsson, 1996), while liver and brain have been reported to have very low dCK activity (Spasokukotskaja et al., 1995). The molecular mechanism that regulates the tissue-specific expression of dCK is not yet clear. dGK is constitutively expressed throughout the cell cycle and the enzyme level is believed to be proportional to the amount of mitochondria in most tissues (Arné & Eriksson, 1995). Northern blot analysis of dGK mRNA suggests that dGK is

| Subcellular location of the dNKs and rNKs |
|------------------------------------------|
| dNKs                        | Subcellular location |
|-----------------------------|----------------------|
| TK1                         | Cytosol              |
| TK2                         | Mitochondria         |
| dCK                         | Nucleus and/or cytosol|
| dGK                         | Mitochondria         |
| rNKs                        | Subcellular location |
| ADK                         | Cytosol              |
| UCK1                        | Nucleus              |
| UCK2                        | Cytosol              |
expressed in most tissues, with highest levels in muscle, brain, liver, and lymphoid tissues (Johansson & Karlsson, 1996).

ADK plays a key role in the regulation of intracellular and extracellular levels of adenosine (Manfredi & Holmes, 1985; Berne, 1993). Adenosine has widespread effects on cardiovascular, nervous, respiratory, and immune systems (Fox & Kelley, 1978; Manfredi & Holmes, 1985). Inhibitors of ADK might play an important pharmacological role in increasing intracellular adenosine concentrations and act as anti-inflammatory agents (Cronstein, 1992; Firestein et al., 1994). With Northern blot analysis of ADK, the corresponding mRNA species of 1.3 and 1.8 kb were detected in all tissues (placenta, liver, muscle, kidney, heart, pancreas, brain, and lung) investigated (Spychala et al., 1996). UCK activity demonstrates no close correlation with cell proliferation (Sköld, 1960b; Weichsel et al., 1972). UCKs are widely distributed and have been purified from mammalian liver, lung, brain, heart, kidney, pancreas, spleen, thymus, bone marrow, testis, skeletal muscle, and small intestine (Herzfeld & Raper, 1979; Shen et al., 1998). Mouse UCK1 mRNA has previously been shown to be expressed in brain tissue (Ropp & Traut, 1996) and human UCK2 mRNA in human testis (Ozaki et al., 1996). We recently demonstrated that human UCK1 mRNA has been detected as 2 isoforms of approximately 1.8 and 2.7 kb in several tissues. The 2.7-kb band is ubiquitously expressed in the investigated tissues, with high level of expression in liver, kidney, skeletal muscle, and heart, whereas low levels are present in brain, placenta, small intestine, and spleen. The band of approximately 1.8 kb is detected in skeletal muscle, heart, liver, and kidney. Human UCK2 mRNA was only detected in placenta as 2 transcripts of approximately 1.2 and 2.0 kb, because testis was not blotted on this Northern blot (Van Rompay et al., 2001). The molecular mechanisms that regulate the tissue-specific expression of UCK1 and/or UCK2 are not yet clear.

4. Nucleoside analogues

4.1. Deoxyribonucleoside analogues

NAs are used in the clinic for treatment of certain viral infections and tumors (Table 3). Recently, current knowledge concerning the molecular mechanisms of activity and resistance to major NAs in cancer treatment has been reviewed (Galmarini et al., 2001, 2002). Anticancer deoxyribonucleoside analogues used in the clinic include 2-chloro-2'-deoxyadenosine (Cladribine, CDa), 2-fluoro-9-β-D-arabinofuranosyladenine (Fludarabine, F-AraA), 1-β-D-arabinofuranosylcytosine (Cytarabine, AraC), and 2',2'-difluorodeoxycytidine (Gemcitabine, dFdC). NAs such as 2',3'-didehydro-3'-deoxythymidine (Stavudine, d4T), and abacavir (ABC) are used in antiviral treatment. Combination therapy, comprising at least 3 anti-HIV drugs, has become the standard treatment of AIDS or HIV-infected patients. The complications, currently used or in advanced clinical trials, belong to one of the following classes: (1) nucleoside reverse transcriptase (RT) inhibitors (NRTIs) (i.e., AZT, ddI, ddC, d4T, 3TC, ABC, or the nucleotide RT inhibitor [NtRTI] tenofovir [PMPA]), (2) non-NRTIs (NNRTIs) (i.e., nevirapine, delavirdine, efavirenz, and emtricitabine), and (3) protease inhibitors (PI) (i.e., saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, and lopinavir) (De Clercq, 2002). Recently, new developments in anti-HIV chemotherapy have been reviewed (Tan et al., 1999; De Clercq, 2002). Here, we will address the currently used NRTIs or antiviral NAs and also anticancer NAs.

Major problems in the treatment of cancer and viral diseases with NAs are acquisition of resistance and side effects such as delayed cytotoxicity. According to Galmarini et al. (2001), there are 3 general mechanisms of resistance to NAs that have been described in cell lines and clinical samples: (1) insufficient intracellular concentrations of NTPs, which might be due to inefficient cellular uptake, decreased levels of activating enzymes, increased catabolism by elevated levels of 5'-NT or deaminases, or expansion of dNTP pools; (2) inability to achieve sufficient alterations in DNA strands or dNTP pools, which might result from altered interactions with DNA polymerases, lack of inhibition of RR, or inadequate p53 exonuclease activity; and (3) defective induction of apoptosis. Zhu (2000) reviews this induction of apoptosis by NAs. The key event of apoptosis is caspase activation, which may be a consequence of death receptor triggering, mitochondrial activation, and possibly other not yet defined initiation events. Thus, the cell death pathway may be initiated at different levels by the different classes of NAs.

Table 3: Deoxyribonucleoside analogues used in anticancer and antiviral therapy

| Drug | dNKs enzyme | Clinical use |
|------|-------------|--------------|
| CdA  | dCK, dGK*   | Hairy cell leukemia, CLL, multiple sclerosis, autoimmune disorders |
| CAFdA | dCK         | Pediatric refractory/relapsed acute myeloid and lymphoblastic leukemia |
| F-AraA | dCK, dGK*   | CLL |
| AraC | dCK         | Acute leukemia, lymphomas |
| dFdC | dCK, TK2*   | Pancreatic cancer, nonsmall cell lung cancer, breast cancer |
| AraC8 | dGK, dCK*   | T-cell acute lymphoblastic leukemia |

* The NA is poorly phosphorylated by this enzyme.

b In clinical trial.

AZT, 2',3'-didehydro-3'-deoxythymidine (Stavudine, d4T), and abacavir (ABC) are used in antiviral treatment. 5'-NT or deaminases, or expansion of dNTP pools; (2) inability to achieve sufficient alterations in DNA strands or dNTP pools, which might result from altered interactions with DNA polymerases, lack of inhibition of RR, or inadequate p53 exonuclease activity; and (3) defective induction of apoptosis. Zhu (2000) reviews this induction of apoptosis by NAs. The key event of apoptosis is caspase activation, which may be a consequence of death receptor triggering, mitochondrial activation, and possibly other not yet defined initiation events. Thus, the cell death pathway may be initiated at different
subcellular compartments, including the plasma membrane, cytosol, mitochondria, and nucleus. A major strategy in the fight against cancers is to induce apoptosis. Incorporation of NAs into nuclear DNA causes DNA strand breaks in S-phase cells and is regarded to be crucial for the initiation of apoptosis. However, there are also other pathways reported that induce apoptosis. The mechanisms that link DNA damage induced by NAs to apoptosis, particularly to mitochondria, are largely unknown. Some studies suggest that mitochondria may be involved in the induction of apoptosis by NAs, and a novel strategy is to selectively target mitochondrial permeabilizing agents to malignant cells (Zhu, 2000; Solary et al., 2003).

NAs are phosphorylated to their triphosphate form and then incorporated into cellular or viral DNA by a cellular or viral DNA polymerase or a RNA polymerase or a viral RT (Fig. 6). The presence of NAs in DNA causes termination of DNA elongation and often also resistance to proofreading exonucleases. While the mechanism of anticancer or antiviral activity of NAs may ultimately be the same, it should be noted that each compound has its own distinct metabolic and pharmacological properties. Some of these analogues also inhibit key enzymes (e.g., RR, TS, or dCMP deaminase) involved in the generation of the purine and pyrimidine nucleotides and RNA synthesis and directly activate the caspase cascade. All of these effects may lead to cell death (Galmarini et al., 2002).

Several studies have provided evidence that dUTP pyrophosphatase (dUTPase) is vital for cellular and, in some cases, viral DNA replication (Fig. 2B) (Ladner, 2001; Payne & Elder, 2001). Aberrant dUTP metabolism plays a critical role in the molecular mechanisms of cell killing induced by inhibitors of dihydrofolate reductase and TS. Under normal conditions, uracil is precluded from DNA by the combined actions of dUTPase and uracil-DNA glycosylase (UDG). However, during TS inhibition, dUTP pools may accumulate and overwhelm dUTPase, resulting in repeated cycles of uracil misincorporation and detrimental repair leading to strand breaks and cell death. Furthermore, herpesviruses (types 1–8), poxviruses, and some nonprimate retroviruses (ELAV, visna, CAEV, and FIV) encode dUTPase, whereas the primate retroviruses (HIV and SIV) do not (Studebaker et al., 2001; Fleischmann et al., 2002). Studies of several virus models have suggested that viral dUTPases may be required for virus replication in resting cells, whereas in proliferating cells cellular dUTPase may substitute for a mutant viral protein (Fleischmann et al., 2002). Cellular and viral dUTPase may be a suitable target for anticancer and antiviral therapy.

Accumulation of the pharmacologically active NA-TP is, however, counteracted by dephosphorylation of NAs by the 5′-NTs and by degradation of the NAs by enzymes involved in nucleoside and nucleotide catabolism. The human dNKs (TK1, dCK, TK2, and dGK), which catalyze the initial and often rate-limiting phosphorylation step, have been investigated in detail (Arner & Eriksson, 1995; Johansson et al., 1999).

dCK has been studied intensively over the years, because the enzyme is responsible for the initial activation of a number of clinically important anticancer and antiviral drugs, such as AraC, F-AraA, CdA, dFdC, ddC, and 3TC (Fig. 7) (Bohman & Eriksson, 1990; Arner & Eriksson, 1995; Johansson & Karlsson, 1995). Impaired dCK expression or activity in cells results in resistance to these drugs, indicating that dCK plays a key role in their metabolism and pharmacological activities (Verhoef et al., 1981; Ullman et al., 1988; Owens et al., 1992; Ruiz van Haperen et al., 1994; Dumontet et al., 1999; Månsson et al., 2003). It has also been shown that sensitivity to dCK-activated NAs increases by overexpression of dCK in dCK-deficient tumor cell lines (Hapke et al., 1996). Moreover, in vitro models have shown cross-resistance among CdA, dFdC, F-AraA, and AraC, with reduced dCK activity as the underlying determinant of resistance (Dumontet et al., 1999).

AraC is a structural analogue of dCyd and is extensively used in the treatment of acute leukemia and lymphomas (Fig. 7 and Table 3). Intracellular penetration of AraC happens by a carrier protein or pump-mediated transport (Wiley et al., 1982; Capizzi et al., 1983). Once inside the cell, AraC is phosphorylated by dCK and pyrimidine nucleoside kinases to the active 5′-triphosphate derivative AraC-TP (Kufe et al., 1984; Van Rompay et al., 1999). AraC cytotoxicity is believed to result from a combination of DNA polymerase inhibition and from incorporation of AraC-TP into DNA, in competition with dCTP. This incorporation causes chain termination, resulting in a block of
DNA synthesis (Kufe et al., 1984). Sustained high cellular concentrations of AraC-TP relative to that of dCTP are thought to favor drug incorporation into replicating DNA, thereby initiating the leukemic cell death associated with therapeutic response. The cytotoxic activity of AraC is limited by characteristics such as metabolic deamination, low affinity for dCK, and rapid elimination of the triphosphate derivative.

The cytostatic agent dFdC is approved for treatment of pancreatic, breast, and nonsmall cell lung cancers (Fig. 7 and Table 3) (Noble & Goa, 1997). It is phosphorylated to its monophosphate by cellular dCK, to the diphosphate form by UMP-CMPK, and to the triphosphate form by NDPKs (Heinemann et al., 1988; Plunkett et al., 1995; Van Rompay et al., 1999). dFdC-MP inhibits deoxycytidylate deaminase, dFdC-DP inhibits RR, and dFdC-TP inhibits DNA synthesis by competitively inhibiting DNA polymerase and by incorporation into replicating DNA (Heinemann et al., 1990). Once the metabolite is incorporated, DNA chain elongation is terminated after the addition of another nucleotide. dFdC does not terminate DNA replication as effectively as AraC, but once dFdC-MP is incorporated, it is more difficult for the cells to excise it from DNA than AraC-MP (Ruiz van Haperen et al., 1993). The reasons that dFdC is and AraC is not active against solid tumors might be multifactorial, including these differences, together with greater lipophi-
licity, masked chain termination, RNA incorporation, and RR inhibition, which are not observed with AraC.

CdA is used for the treatment of lymphoproliferative disorders such as hairy cell leukemia and chronic lymphocytic leukemia (CLL) as well as for therapy of multiple sclerosis and autoimmune disorders (Fig. 7 and Table 3) (Beutler et al., 1996). Its efficacy, however, is compromised by the emergence of resistant cells. Knowledge about the mechanism of CdA cytotoxicity is limited, and most studies have focused on the activation and/or deactivation of the drug (Carson et al., 1983). Among other proposed mechanisms of action of CdA are incorporation of the analogue into DNA, inhibition of RR, inhibition of DNA repair, DNA strand break accumulation, and activation of poly(ADP-ribose) polymerase (Plunkett & Gandhi, 1996). CdA has also been shown to cause direct alterations in mitochondrial function that might trigger apoptosis. It disrupts the integrity of mitochondria, leading to the release of the proapoptotic mitochondrial protein cytochrome c. A recent study generated 3 cell lines resistant to CdA, with differing levels of initial phosphorylating enzymes dCK/dGK (Chandra et al., 2002). The 3 cell lines had lowered dCK enzyme activity and heightened dGK activity. Consequently, the resistant cell lines accumulated different levels of the phosphorylated drug, CdA-TP, intracellularly. The mechanisms of resistance to CdA did not solely correlate with the CdA-TP accumulation but also may be dictated by changes in Ca^2+-sensitive mitochondrial events (Chandra et al., 2002). 2-Chloro-2'-fluoro-9-(β-D-arabinofuranosyl)adenine (CAFdA, Clofarabine) is a new 2'-arabinofuranosyl derivative of CdA (Fig. 7 and Table 3), which has been used in a phase I clinical trial with encouraging preliminary results (Waud et al., 2000) and the phase II clinical trial for pediatric refractory/relapsed acute myeloid and lymphoblastic leukemia has just been finished (Kantarjian et al., 2003). In human leukemia cell lines is CAFdA, a more efficient substrate for dCK, and the active form is more stable due to higher phosphorylation and longer retention time compared with CdA, but the mechanisms leading to acquired resistance to CAFdA seem to be similar to those for CdA (Lotfi et al., 1999; Månsson et al., 2003).

F-AraA is a structural analogue of Ado and is used in the treatment of CLL (Fig. 7 and Table 3) (Keating, 1999). Therapeutic results in advanced CLL are still unsatisfactory in terms of complete remission achievement and duration in spite of the extensive use of purine analogues (Johnson et al., 2003). The standard therapy remains the alkylating agent Chlorambucil (Rai et al., 2000). More recently, the combination of F-AraA with Chlorambucil has emerged as an approach; unfortunately, it might coincide with a significantly higher incidence of major infections and a higher healthcare cost (Rai et al., 2000). F-AraA is administered as F-AraA-MP to make it more water soluble but is rapidly dephosphorylated by serum phosphatases and the membrane-bound 5'-NT, CD73, into F-AraA that is transported inside the cell via a carrier protein (Baldwin et al., 1999). Like other NAs, it requires phosphorylation to its triphosphate form, F-AraA-TP, for cytotoxicity activity (Plunkett & Saunders, 1991). F-AraA, like CdA, is cytotoxic against both dividing and resting cells. In dividing cells, this compound inhibits DNA synthesis and RR, consequently reducing the pool of dNTPs required for DNA synthesis and enhancing their own cytotoxicity by self-potentiation (Plunkett et al., 1993). Other enzyme targets of F-AraA include DNA primase, DNA polymerase α, DNA ligase, and DNA topoisomerase II (Tseng et al., 1982). Thus, the mechanism of action of F-AraA in proliferating cells is mainly cell cycle specific, and incorporation of F-AraA into DNA during S phase is required for the induction of apoptosis (Consoli et al., 1998; Galmarini et al., 2001, 2002). In nondividing cells, the inhibition of cellular DNA repair is the most likely explanation for cytotoxicity of F-AraA and CdA. Incorporation of F-AraA-TP or CdA-TP into DNA by the repair mechanisms leads to the progressive accumulation of DNA single-strand breaks eventually responsible for apoptosis by both p53-dependent and p53-independent pathways (Sandoval et al., 1996). Another consequence of these treatments is the direct activation of the caspase-9 and caspase-3 pathways by F-AraA-TP and CdA-TP, which are nucleotide activators of Apaf-1 (Gemini et al., 2000). Moreover, F-AraA and CdA also alter gene transcription, resulting in depletion of proteins required for cell survival. Incorporation of F-AraA-MP into RNA results in premature termination of the RNA transcript, impairing its function as a template for protein synthesis, while F-AraA-TP inhibits RNA synthesis by suppressing the activity of RNA polymerase II (Huang et al., 2000). On the other hand, incorporation of CdA metabolites present in one or both DNA strands reduced the yield of full-length transcripts (Hentosh & Tibudan, 1995). In conclusion, inhibition of DNA repair, termination of mRNA transcription, and consequent depletion of proteins required for cell survival as well as the capacity of F-AraA-TP to activate the apoptotic pathway appear to contribute to the cytotoxicity of F-AraA in nondividing cells.

Among the AIDS drugs approved by the Food and Drug Administration (FDA) for clinical use, 2 are modified cytosine analogues, 3TC and ddC (Fig. 7 and Table 3). Similar to other dideoxynucleosides, these analogues are metabolically activated to the triphosphate form that is incorporated into DNA by HIV-RT, resulting in DNA chain termination and ultimately cessation of viral replication. 3TC is the only FDA-approved NA containing an unnatural β-D-nucleoside conformation. 3TC has been shown to be more potent and less toxic than the β-D-isomer (Chang et al., 1992a). The mechanistic basis for the stereochemical selectivity and different toxicity of the isomeric 3TC and ddC compounds is not completely understood (Anderson, 2002). The enzyme responsible for the formation of 3TC-MP is dCK (Chang et al., 1992b). 3TC-MP is incorporated into proviral DNA by HIV-RT and thus acts as a chain termina-
tor. It is also incorporated into the cellular DNA chain by polymerase $\gamma$; however, polymerase $\gamma$ retains its 3',5'-exonuclease activity and is able to excise 3TC-MP from the 3' end of the chain. This may explain the low mitochondrial toxicity of 3TC (Gray et al., 1995). 3TC is neither intracellularly deaminated nor degraded via phosphorolytic cleavage by pyrimidine nucleoside phosphorylase (Coates et al., 1992). 3TC shows significant anti-HIV activity with less toxicity than AZT, and AZT-resistant HIV strains are not cross-resistant to 3TC (Soudery et al., 1991).

(−)FTC (2',3'-dideoxy-5-fluoro-3'-thiacytidine, Emtricitabine) is in phase III trial for HIV and phase I/II trial for hepatitis B virus (HBV); it is considered for use in the multidrug combination therapy for HIV and HBV infections (De Clercq, 2002). The (−)FTC-TP is a competitive inhibitor of HIV-RT and (−)FTC-MP may be incorporated into proviral DNA as a chain terminator (Furman et al., 1992; Schinazi et al., 1992).

ddC shows potent and selective anti-HIV activity in human cells (Mitsuya & Broder, 1986). In various cell lines, ddC is phosphorylated intracellularly to ddC-MP, ddC-TP, and ddC-TP with concentrations at the same order of magnitude (Cooney et al., 1986). The affinity of ddC-TP to DNA polymerase $\alpha$ is very poor but is intermediate to polymerase $\beta$ and high to polymerase $\gamma$ (Starnes & Cheng, 1987). Compared with the other FDA-approved antiviral NAs, ddC has the highest potency of inhibiting mtDNA synthesis (Chen et al., 1991).

dGK has become of interest because the enzyme phosphorylates a number of clinically important anticancer drugs, such as CdA, 9-β-D-arabinofuranosylguanine (Nelarabine, AraG), and 2', 2'-difluorodeoxyguanosine (dFdG) (Wang et al., 1993; Amér & Eriksson, 1995; Sjöberg et al., 1998). Zhu et al. (1998a) showed in vitro that dGK is important for AraG and dFdG phosphorylation, whereas dCK is the most important enzyme for activation of CdA and dFdC (Zhu et al., 1998a). Overexpression of dGK in pancreatic cancer cell lines increases the sensitivity to the purine NAs AraG, dFdG, and CdA (Zhu et al., 1998b).

CdA, AraG, and dFdG are efficiently phosphorylated by mitochondrial dGK (Wang et al., 1993; Zhu et al., 1998a, 1998b, 2000) and have early effects on mitochondrial function (Hentosh & Tibudan, 1997; Zhu et al., 2000). However, it is not clear if there is a relationship between cell death and mtDNA incorporation of antiviral NAs. Several clinically used antiviral NAs have been reported to be incorporated into the mitochondria DNA and thereby cause severe side effects (Lewis & Dalakas, 1995; Agarwal & Olivero, 1997; Barile et al., 1998; Chariot et al., 1999). These effects are related to their mtDNA incorporation and described as delayed effects, which occur after several weeks or months of drug exposure (Lewis et al., 1996; Dalakas, 2001). The role of the mitochondrial enzymes for mitochondrial toxicity and the different mechanisms behind delayed and acute toxicity of NAs are not yet clear (Moyle, 2000).

The prodrug of the biologically active AraG has proven very efficient, especially in the treatment of patients with T-cell acute lymphoblastic leukemia (Fig. 7 and Table 3) (Aguayo et al., 1999). AraG is a substrate of both dGK and dCK, and at low substrate concentrations, dGK seems to be the preferred enzyme (Zhu et al., 1998a; Rodriguez et al., 2002). Although the mechanisms of AraG are not fully understood, the accumulation of AraG-TP has been correlated with cytotoxicity both in vitro and in vivo (Scharenberg et al., 1986). Once phosphorylated to its triphosphate derivative, AraG-TP acts as a structural analogue of dGTP and is thereby incorporated into DNA. It has been demonstrated that the accumulation of AraG-TP is independent of the cell cycle, which is not surprising because both dGK and dCK are expressed throughout the cell cycle. Furthermore, it has been suggested that AraG exerts its cytotoxic action by inducing apoptosis and that incorporation of AraG-TP into nuclear DNA is a critical event for triggering apoptosis (Rodriguez & Gandhi, 1999). These data are confirmed in a MOLT-4 leukemia cell line where the results suggest that the resistance to apoptosis in AraG-resistant cells might contribute to the overall insensitivity to a variety of anticancer drugs (Månsson et al., 2002). A recent study has also suggested a role of mitochondria in the cell-specific toxicity of dGTP with intramitochondrial accumulation of dGTP and inhibition of mtDNA (Arpaia et al., 2000). We have shown that AraG can be incorporated into mtDNA, but we do presently not know to what extent the mitochondrial incorporation contributes to the cytotoxic action of the analogue (Curbo et al., 2001). We have also shown that the acute cytotoxicity of AraG is not caused by mtDNA damage (Curbo, 2001). However, it cannot be excluded that long-term exposure to AraG may cause mtDNA alterations with subsequent delayed mitochondrial toxicity. Several in vitro studies have been performed on the molecular mechanisms of resistance to AraG, with partly conflicting results. We recently reported that AraG resistance occurs by 2 separate sequentially mechanisms. The first mechanism is associated with a decrease of AraG incorporation into mtDNA and the second event is associated with loss of dCK activity but not with loss of dGK activity (Curbo et al., 2001). Recent results indicate that mutations in the genes encoding for dGK and TK2 are associated with mtDNA depletion (Mandel et al., 2001; Saada et al., 2001). However, we could demonstrate that AraG did not cause mtDNA depletion or altered translation of mtDNA encoded genes (Curbo, 2001). In conclusion, further studies are necessary to enlighten the many molecular mechanisms associated with AraG resistance.

TK1 phosphorylates the pyrimidine analogues AZT, 1-(2'-deoxy-2'-fluoro-5'-β-D-arabinofuranosyl)-5-iodouracil (Fia-luridine, FIAU), and d4T (Fig. 7 and Table 3) (Furman et al., 1986; Munch-Petersen et al., 1991; Ahluwalia et al., 1996; Wang & Eriksson, 1996).

The introduction of AZT into clinical practice in 1987 ushered in the therapeutic era of the AIDS epidemic. AZT is
a thymidine analogue that is mainly phosphorylated by TK1. However, TK2 has been suggested to be phosphorylated by important for the activation of AZT in nondividing cells that lack TK1 (Armér et al., 1992). Following AZT-MP entry into the mitochondria, 2 mechanisms of mitochondrial cytoxicity are possible. Studies have suggested a hypothesis for mitochondrial toxicity: following phosphorylation to AZT-TP, DNA polymerase γ is inhibited either by AZT-TP serving as a competitive substrate and incorporation into mtDNA or by terminating the mtDNA chain noncompetitively (Lewis & Dalakas, 1995). However, other studies have concluded that AZT-TP is not responsible for mitochondrial toxic effect observed during chronic administration (Szebeni et al., 1991). Secondly, AZT-MP is an alternative substrate inhibitor of dTMP for dTMPK (Furman et al., 1986; Lavie et al., 1997). This may result in decreased dTTP in the mitochondria and thus decreased mtDNA synthesis (Törnevik et al., 1995; Lavie et al., 1997). In conclusion, although the mechanism by which AZT causes mitochondrial toxicity requires full elucidation, recently, there is evidence provided that AZT-MP is primarily responsible for the toxicity and that this anabolite is mainly formed in the cytosol (Sales et al., 2001). 3′-Azido-3′-deoxy-5′-thymidyllic acid, mono [3-(dodecylthio)-2-decyloxycarbonyl] ester, sodium salt (FZD, Fozivudine tidoxil), belonging to the newer AZT generation drugs, is a thioether lipid AZT conjugate that has recently passed phase II clinical trials. Intracellularly, FZD is split into the lipid moiety and AZT-MP, the latter of which is subsequently phosphorylated to the active metabolite AZT-TP. FZD appears to be as effective as and potentially better tolerated than AZT and has the advantage of once daily intake (Girard et al., 2000).

d4T like AZT is an anti-HIV drug. The phosphorylation of d4T to its d4T-MP is the rate-limiting step of the sequential conversion of d4T to d4T-TP, which inhibits HIV-RT equipotently as AZT-TP. DNA polymerase γ is inhibited either by AZT-TP serving as a competitive substrate and incorporation into mtDNA or by terminating the mtDNA chain noncompetitively (Lewis & Dalakas, 1995). However, other studies have concluded that AZT-TP is not responsible for mitochondrial toxic effect observed during chronic administration (Szebeni et al., 1991). Secondly, AZT-MP is an alternative substrate inhibitor of dTMP for dTMPK (Furman et al., 1986; Lavie et al., 1997). This may result in decreased dTTP in the mitochondria and thus decreased mtDNA synthesis (Törnevik et al., 1995; Lavie et al., 1997). In conclusion, although the mechanism by which AZT causes mitochondrial toxicity requires full elucidation, recently, there is evidence provided that AZT-MP is primarily responsible for the toxicity and that this anabolite is mainly formed in the cytosol (Sales et al., 2001). 3′-Azido-3′-deoxy-5′-thymidyllic acid, mono [3-(dodecylthio)-2-decyloxycarbonyl] ester, sodium salt (FZD, Fozivudine tidoxil), belonging to the newer AZT generation drugs, is a thioether lipid AZT conjugate that has recently passed phase II clinical trials. Intracellularly, FZD is split into the lipid moiety and AZT-MP, the latter of which is subsequently phosphorylated to the active metabolite AZT-TP. FZD appears to be as effective as and potentially better tolerated than AZT and has the advantage of once daily intake (Girard et al., 2000).

Recent advances in the understanding of AZT metabolism and toxicity have led to the development of new analogues designed to improve pharmacokinetics and reduce toxicity. FAM (2′′-Fluoro-2′′-deoxyarabinofuranosylthymidine) is a thymidine analogue that is mainly phosphorylated by TK1. However, TK2 has been suggested to be phosphorylated by important for the activation of AZT in nondividing cells that lack TK1 (Armér et al., 1992). Following AZT-MP entry into the mitochondria, 2 mechanisms of mitochondrial cytoxicity are possible. Studies have suggested a hypothesis for mitochondrial toxicity: following phosphorylation to AZT-TP, DNA polymerase γ is inhibited either by AZT-TP serving as a competitive substrate and incorporation into mtDNA or by terminating the mtDNA chain noncompetitively (Lewis & Dalakas, 1995). However, other studies have concluded that AZT-TP is not responsible for mitochondrial toxic effect observed during chronic administration (Szebeni et al., 1991). Secondly, AZT-MP is an alternative substrate inhibitor of dTMP for dTMPK (Furman et al., 1986; Lavie et al., 1997). This may result in decreased dTTP in the mitochondria and thus decreased mtDNA synthesis (Törnevik et al., 1995; Lavie et al., 1997). In conclusion, although the mechanism by which AZT causes mitochondrial toxicity requires full elucidation, recently, there is evidence provided that AZT-MP is primarily responsible for the toxicity and that this anabolite is mainly formed in the cytosol (Sales et al., 2001). 3′-Azido-3′-deoxy-5′-thymidyllic acid, mono [3-(dodecylthio)-2-decyloxycarbonyl] ester, sodium salt (FZD, Fozivudine tidoxil), belonging to the newer AZT generation drugs, is a thioether lipid AZT conjugate that has recently passed phase II clinical trials. Intracellularly, FZD is split into the lipid moiety and AZT-MP, the latter of which is subsequently phosphorylated to the active metabolite AZT-TP. FZD appears to be as effective as and potentially better tolerated than AZT and has the advantage of once daily intake (Girard et al., 2000).

4.2. Ribonucleoside analogues

Most ribonucleoside analogues have so far not been investigated in detail. Adenosine has diverse effects on the cardiovascular, nerve, respiratory, and immune systems (Fox & Kelley, 1978; Manfredi & Holmes, 1985). Inhibitors of ADK play an important pharmacological role in increasing extracellular adenosine concentrations (Cronstein, 1992; Firestein et al., 1994). Examples of ADK inhibitors are 5′-amino-5′-deoxyadenosine, 5′-iodotubercidine, and 5′-deoxy-5′-iodotubercidine (Kowaluk et al., 1999); recently, many promising new compounds like ABT-702 (Jarvis et al., 2000), GP515 (Siegmund et al., 2001), and a variety of pyrrolo[2,3- d]pyrimidine NAs (Ugarkar et al., 2000) have been synthesized and tested.
ADK exhibits a relatively broad substrate specificity tolerating modifications in both sugar and base moieties (Miller et al., 1979). Accordingly, certain nucleoside antiviral and anticancer drugs are substrates of ADK and consequently undergo rapid phosphorylation in vivo to the 5'-monophosphate. In many cases, the monophosphate is subsequently converted by other kinases to the triphosphate, which functions as the active metabolite. Examples include the antiviral drug ribavirin (Willis et al., 1978) and the immunosuppressive drug mizoribine (Yamada et al., 1981).

Ribonucleoside analogues, such as ribavirin, have been demonstrated to be active as anti-RNA virus compounds (Loeb et al., 1999; Crotty et al., 2000). The mechanism of action for ribavirin was recently demonstrated to be through an “error catastrophe” induced by mutagenic incorporation of ribavirin triphosphate into the RNA genome of HIV virus (Loeb & Mullins, 2000). Whether other rNks may be a tool to increase the activation of ribonucleoside analogues in virus-infected cells and thereby suppress the development of resistant virus should be further investigated.

The recent identified UCKs phosphorylate, and thereby pharmacologically activate, several cytotoxic pyrimidine ribonucleoside analogues that may have pharmacological use in chemotherapy of cancer. UCK1 and UCK2 phosphorylated several of the 28 tested cytidine and uridine NAs, such as 6-azauridine, 5-fluorouridine, 5-fluorocytidine, and 2-thiocyctidine (Van Rompay et al., 2001). Several pyrimidine ribonucleoside analogues like 6-azauridine (Paternak et al., 1961; Vesely & Cihak, 1973a), 5-aza-cytidine (Cihak & Broucek, 1972; Vesely & Cihak, 1973b), 5-hydroxycytidine (Smith & Visser, 1965), and 4-thiouridine (Lindsay & Yu, 1974) exert the pharmacological effects in their monophosphate forms by inhibiting OMP decarboxylase in addition to their incorporation into RNA or DNA (Anderson, 1973). The different mode of actions of ribonucleoside analogues makes this group of compounds interesting for further studies to develop clinically useful drugs. Promising results in animal tumor models have recently been shown for 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)-cytosine and -uracil (Takatori et al., 1999). Cyclopentenyl cytosine is another interesting compound with antitumor activity that presently is evaluated in clinical trials (Verschuur et al., 2000). Overexpression of human UCK1 and UCK2 in fusion with GFP in a Chinese hamster ovary (CHO) cell line increased sensitivity to certain pyrimidine ribonucleoside analogues (Van Rompay, 2001). Expression of UCK1-GFP increased sensitivity to 6-azacytidine and 5-methylcytidine, while UCK2-GFP overexpression resulted in an increased sensitivity to 3-deaza-uridine and 6-azauridine and a small increase to 5-methylcytidine. No difference in the cytotoxicity of the base analogue 5-fluorouracil was observed in the UCK-overexpressing cells compared with the parent cancer cell lines, which is in agreement with recent literature (Mascia & Ipata, 2001).

5. Concluding remarks

The cloning, recombinant expression, and characterization of the nucleoside and nucleotide kinases will allow the pathways of nucleoside and NA metabolism to be outlined in more detail. Knowledge of the metabolic pathways will be important for the development of novel antiviral and anticancer ribonucleoside and deoxyribonucleoside analogues and for the characterization of their pharmacological activation in different tissues.

In mammalian cells, DNA replicates in the nucleus and in the mitochondria. The enzymes responsible for the synthesis of deoxyribonucleotides are located in the cytosol, the nucleus, and the mitochondria. The cytosol and the nucleus are separated by the nuclear membrane, which allows diffusion of small proteins and nucleotides. The deoxyribonucleotide pools in the nucleus and cytosol are thereby metabolically related and equilibrated. The deoxyribonucleotide pool in the mitochondria is structurally separated from the pool in the cytosol by the mitochondrial membrane. The mitochondrion contains an inner and an outer membrane; the outer membrane is permeable to small molecules (up to 10 kDa), whereas the inner membrane is almost impermeable to passage of ions and most molecules at physiological conditions. However, the nucleosides can enter the mitochondria by membrane transport proteins. The mitochondrial dNks dG and Tk2 phosphorylate all 4 deoxyribonucleosides required for DNA synthesis in mitochondria. In addition to the first phosphorylation step, there are also 2 mitochondrial NDPks identified for the third phosphorylation step. A question remains for the second phosphorylation step, because little is known about mitochondrial NMPks. Two mitochondrial AKs have been demonstrated, which may be responsible for dAMP phosphorylation, but the enzymes phosphorylating dCMP, dGMP, and dTMP within the mitochondria remain to be identified. Because several clinically used NAs cause severe side effects through mitochondrial toxicity, it is important to identify and characterize the mitochondrial enzymes that may contribute to this toxicity.

An interesting future study is to focus on the identification and use of ribonucleoside analogues to induce mutations of RNA viruses, such as HIV, heptatis C virus (HCV), and severe acute respiratory syndrome (SARS) (Loeb et al., 1999; Crotty et al., 2000; Cinatl et al., 2003; Nie et al., 2003). Ribonucleoside analogues, such as ribavirin, have been demonstrated to be active as anti-RNA virus compounds (Crotty et al., 2000; Loeb & Mullins, 2000; Nie et al., 2003). RNA viral diseases are responsible for a majority of viral morbidity and mortality of viral diseases, including measles, polio, influenza, AIDS, and hepatitis C. The idea is that RNA NAs will be administered to an infected cell, and the analogue is then incorporated by a polymerase into a RNA copy of the genomic nucleic acid encoding the virus. Subsequent copying of the incorporated analogue will cause an increase in the mutation rate of the virus. Over time, this...
results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication. Further investigation of the recently cloned rNks, which is considered the rate-limiting step, and the next 2 phosphorylation steps (NMPK and NDPK) of cellular and viral RNA polymerases will contribute to develop better RNA incorporated ribonucleoside and ribonucleotide analogues. Purine ribonucleoside analogues should also be investigated as possible RNA virus inhibitors.

Acknowledgments

This work was supported by grants from the Karolinska Institute, the Swedish Medical Research Council, the Swedish Cancer Society, and the European Commission. We are also indebted to Dirk de Weerd (Department of Nephrology-Hypertension) for editing the figures.

References

Absil, J., Tuille, M., & Roux, J. M. (1980). Electrophoretically distinct forms of uridine kinase in rat. Tissue distribution and age-dependence. *Biochim J* 185, 273–276.

Agarwal, R. P., & Olivero, O. A. (1997). Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3'-azido-2',3'-dideoxymidine. *Mutat Res* 390, 223–231.

Aguayo, A., Cortes, J. E., Kantarjian, H. M., Beran, M., Gandhi, V., Plunkett, W., Kurtzberg, J., & Keating, M. J. (1999). Complete hematologic and cytogenetic response to 2-amino-9-(N,N-di-3-hydroxy-9H-purin-2-yl)guanine in a patient with chronic myelogenous leukemia in T cell blastic phase: a case report and review of the literature. *Cancer* 85, 58–64.

Ahlulwalia, G. S., Gao, W. Y., Mitsuya, H., & Johns, D. G. (1996). 2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis. * Mol Pharmacol* 50, 160–165.

Ahmed, N. K., & Baker, D. R. (1980). Properties of uridine-cytidine kinase derived from L1210 leukemia cells. *Cancer Res* 40, 3559–3563.

Ahmed, N. K., & Welch, A. D. (1979). Some properties of uridine-cytidine kinase from a human malignant lymphoma. *Cancer Res* 39, 3102–3106.

Anderson, E. P. (1973). Nucleoside and nucleotide kinetics (Review). In P. D. Boyer (Ed.), *The Enzymes*, vol. 9 (3rd ed.) (pp. 49–96). New York: Academic Press.

Anderson, K. S. (2002). Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase. *Biochim Biophys Acta* 1587, 296–299.

Anderson, E. P., & Brockman, R. W. (1964). Feedback inhibition of uridine kinase by cytidine triphosphate and uridine triphosphate. *Biochim Biophys Acta* 91, 380–386.

Andres, C. M., & Fox, I. H. (1979). Purification and properties of human placenta adenosine kinase. *J Biol Chem* 254, 11388–11393.

Arné, E. S. J., & Eriksson, S. (1995). Mammalian deoxyribonucleoside kinases. *Pharmacol Ther* 67, 155–186.

Arné, E. S. J., Spasokouktskaia, T., & Eriksson, S. (1992). Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. *Biochem Biophys Res Common* 188, 712–718.

Arpaia, E., Benveniste, P., Di Cristiano, A., Gu, Y., Dalal, I., Kelly, S., Hershfield, M., Pandolfi, P. P., Reisfman, C. M., & Cohen, A. (2000). Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. *J Exp Med* 191, 2197–2208.

August, E. M., Birks, E. M., & Prusoff, W. H. (1991). 3'-Deoxythymidin-2'-one permeation of human lymphocyte H9 cells by nonfacilitated diffusion. *Mol Pharmacol* 39, 246–249.

Baldwin, S. A., Mackey, J. R., Cass, C. E., & Young, J. D. (1999). Nucleoside transporters: molecular biology and implications for therapeutic development (Review). * Mol Med Today* 5, 216–224.

Balzarini, J., Herdevijin, P., & De Clercq, E. (1989). Differential patterns of intracellular metabolism of 2',3'-dideoxy-2',3'-dideoxynucleoside, two potent anti-human immunodeficiency virus compounds. *J Biol Chem* 264, 6127–6133.

Balzarini, J., Zhu, C., De Clercq, E., Périz-Pérez, M. J., Chamorro, C., Camarasa, M. J., & Karlsson, A. (2000). Novel ribofuranosynucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase 2. *Biochem J* 351, 161–171.

Balzarini, J., Degreve, B., Zhu, C., Durini, E., Porcu, L., De Clercq, E., Karlsson, A., & Manfredini, S. (2001). 2'-O-acyl/alkyl-substituted arabinosyl nucleosides as inhibitors of human mitochondrial thymidine kinase. *Biochem Pharmacol* 61, 727–732.

Balzarini, J., Hernandez, A. I., Roche, P., Ensouf, R., Karlsson, A., Camarasa, M. J., & Perez-Perez, M. J. (2003). Non-nucleoside inhibitors of mitochondrial thymidine kinase (TK-2) differentially inhibit the closely related herpes simplex virus type 1 TK and Drosophila melanogaster multifunctional deoxynucleoside kinase. *Mol Pharmacol* 63, 263–270.

Barile, M., Volanti, D., Quagliariello, E., & Passarella, S. (1998). Mitochondria as cell targets of AZT (zidovudine). *Gen Pharmacol* 31, 531–538.

Berne, R. M. (1993). Adenosine: a cardioprotective and therapeutic agent. *Cardiovasc Res* 27, 2.

Beutler, E., Sipe, J. C., Romine, J. S., Kozial, J. A., McMillan, R., & Zyroff, J. (1996). The treatment of chronic progressive multiple sclerosis with cladribine. *Proc Natl Acad Sci USA* 93, 1716–1720.

Bohman, C., & Eriksson, S. (1990). Mammalian deoxynucleoside kinases. *Biochim Biophys Acta Adv* 9, 11–35.

Bradhshaw Jr., H. D. (1984). Human thymidine kinase gene: molecular cloning and nucleotide sequence of a cDNA expressible in mammalian cells. *Mol Cell Biol* 4, 2316–2320.

Burton, T. R., Kashour, T., Wright, J. A., & Amara, F. M. (2003). Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review). *Int J Oncol* 22, 21–31.

Canellakis, E. S. (1957). Pyrimidine metabolism. II. Enzymatic pathway of uracil anabolism. *Biochim Biophys Acta* 264, 727–732.

Carbone, A. R. Van Rompay et al. / Pharmacology & Therapeutics 100 (2003) 119–139
Chariot, P., Drougl, I., de Lacroix-Szmania, I., Eliezer-Vanerot, M. C., Chazaud, B., Lombes, A., Schaeffer, A., & Zaffran, E. S. (1999). Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 30, 156 – 160.

Chen, C. H., Varquez-Padua, M., & Cheng, Y. C. (1991). Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 39, 625 – 628.

Cheng, N., Payne, R. C., & Traut, T. W. (1986). Regulation of uridine kinase. Evidence for a regulatory site. J Biol Chem 261, 13006 – 13012.

Chottiner, E. G., Shewach, D. S., Datta, N. S., Ashcraft, E., Gribbin, D., Ginsburg, D., Fox, I. H., & Mitchell, B. S. (1991). Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci USA 88, 1531 –1535.

Cihak, A., & Broucek, J. (1972). Dual effect of 5-azacytidine on the synthesis of liver RNA. Lack of the relationship between metabolic transformation of organic acid in vitro and its incorporation in vivo. Biochem Pharmacol 21, 2497 – 2507.

Cihak, A., & Rada, B. (1976). Uridine kinase: properties, biological significance and chemotherapeutic aspects (a review). Neoplasma 23, 233 – 257.

Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. W. (2003). Glycyrhrizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361 (9374), 2045 – 2046.

Coates, J. A. V., Cammaack, N., Jenkinson, H. J., Mutton, I. M., Pearson, B. A., Storer, R., Cameron, J. M., & Penn, C. R. (1992). The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 36, 202 – 205.

Consoli, U., El-Tounsi, I., Sandoval, A., Snell, V., Kleine, H. D., Brown, W., Robinson, J. R., DiRaimondo, F., Plunkett, W., & Andreeff, M. (1998). Differential induction of apoptosis by fludarabine monophosphate in leukemia B and normal T cells in chronic lymphocytic leukemia. Blood 91, 1742 – 1748.

Cook, W. J., Delucia, L. J., & Chattopadhyay, D. (2000). Crystal structure of adenosine kinase from Toxoplasma gondii at 1.8 Å resolution. Protein Sci 9, 704 – 712.

Cooney, D. A., Dalal, M., Mitsuya, H., McMahon, J. B., Mitsuya, J., & McMahon, J. B. (1987). Growth inhibition of human tumor xenografts by 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 35, 265 – 268.

Cronstein, B. N. (1992). Molecular mechanism of methotrexate action in inflammation. Inflammation 16, 411 – 423.

Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y., Hong, Z., Andino, R., & Cameron, C. E. (2000). Common resistance mechanisms to deoxyadenosine and deoxythymidine nucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 106, 78 – 85.

Durham, J. P., & Ives, D. H. (1972). Intracellular distribution of pyrimidine nucleoside phosphorylating activities in rat thymus. Exp Cell Res 70, 97 –105.

Elliots, P. H., & Van der Weyden, M. B. (1981). Kinetic mechanisms and inhibition of human liver thymidine kinase. Biochim Biophys Acta 660, 238 – 242.

Eriksson, S., & Wang, L. (1997). Substrate specificities, expression and primary sequences of deoxynucleoside kinases; implication for chemotherapy. Nucleosides Nucleotides 16, 653 – 659.

Firestein, G. S., Boyle, D., Bullough, D. A., Gruber, H. E., Sajjadi, F. G., Montag, A., Sambol, B., & Mullane, K. M. (1994). Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 152, 5853 – 5859.

Fleischmann, J., Kremmer, E., Greenspan, J. S., Grässer, F. A., & Niedobitek, G. (2002). Expression of viral and human dUTPase in Epstein-Barr virus associated diseases. J Med Virol 68, 568 – 573.

Fox, I. H., & Kelley, W. N. (1978). The role of adenosine and 2′-deoxyadenosine in mammalian cells. Ann Rev Biochem 47, 655 – 686.

Francke, U., & Thompson, L. (1979). Regional mapping, by exclusion of adenylate kinase on human chromosome 10 using the gene dosage approach. Cytogenet Cell Genet 25, 156.

Fulchignoni-Lataud, M. C., & Roux, J. -M. (1984). Uridine kinase molecular species and uridine uptake in some variants of rat hepatomas. J Cell Physiol 118, 34 – 38.

Fulchignoni-Lataud, M. C., Tuillie, M., & Roux, J. -M. (1976). Uridine-cytidine kinase from foetal and adult rat liver: purification and study of some properties. Eur J Biochem 69, 217 – 222.

Furman, P. A., Fyfe, J. A., St Clair, M. H., Weinhold, K., Rideout, J. L., Freeman, G. A., Lehrman, S. N., Bolognesi, D. P., Broder, S., Mitsuya, H., & Barry, D. W. (1986). Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83, 8333 – 8337.

Furman, P. A., Davis, M., Liotta, D. C., Paff, M., Frick, L. W., Nelson, D. J., Domisie, R. E., Winter, J. A., Wilson, L. J., Fyfe, J. A., Tuttle, J. V., Miller, W. H., Condrea, L., Avrett, D. R., Schinazi, R. F., & Painter, G. R. (1992). The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (−) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 36, 2686 – 2692.

Galmarini, C. M., Mackey, J. R., & Dumontet, C. (2001). Nucleoside analogues: mechanism of drug resistance and reversal strategies. Leukemia 15, 875 – 890.

Galmarini, C. M., Mackey, J. R., & Dumontet, C. (2002). Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3, 415 – 424.

Genini, D., Adachi, S., Chao, Q., Ross, D. W., Carrera, C. J., Cottam, H. B., Carson, D. A., & Leoni, L. M. (2000). Deoxyadenosine analogues induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96, 3537 – 3543.

Gentry, G. A. (1992). Viral thymidine kinases and their relatives. Pharmacol Ther 54, 319 – 355.

Girard, P. M., Pegram, P., Siquet, B., Anderson, R., Rafili, F., Tubiana, R., Sereni, D., & Boerner, D. (2000). Phase II placebo-controlled trial of fosfuvudine tidoxil for HIV infection: Pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr 23, 227 – 235.

Gower Jr., W. R., Carr, M. C., & Ives, D. H. (1979). Deoxycytidine kinase. Distinct molecular forms in mitochondria and cytosol. J Biol Chem 254, 2180 – 2183.

Gray, N. M., Marr, C. L., Penn, C. R., Cameron, J. M., & Bethell, R. C. (1995). The intracellular phosphorylation of (−) and (−) 3′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Biochem Pharmacol 50, 1043 – 1051.

Greenberg, G. R., & Hilfinger, J. M. (1996). Regulation of synthesis of ribonucleotide reductase and relationship to DNA replication in various systems. Prog Nucleic Acid Res Mol Biol 53, 345 – 395.
Greenberg, M., Shum, D. E., & Wee, T. E. (1977). Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma. *Biochem J* 164, 379–387.

Hapke, D. M., Stegmann, A. P., & Mitchell, B. S. (1996). Retroviral transfer of deoxyuridine kinase into tumor cell lines enhances nucleoside toxicity. *Cancer Res* 56, 2343–2347.

Hatzis, P., Al-Madhoon, A. S., Jullig, M., Petракis, T. G., Eriksson, S., & Talianidis, I. (1998). The intracellular localization of deoxycytidine kinase. *J Biol Chem* 273, 30239–30243.

He, Q., Skog, S., Wang, N., Eriksson, S., & Tribukait, B. (1996). Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. *Eur J Cell Biol* 70, 117–124.

Heinemann, V., Hertel, L. W., Grindey, G. B., & Plunkett, W. (1988). Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. *Cancer Res* 48, 4024–4031.

Heinemann, V., Xu, Y. Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plunkett, W. (1990). Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. *Mol Pharmacol* 38, 567–572.

Hentosh, P., & Tibudan, M. (1995). In vitro transcription of DNA containing 2-chloro-2-deoxyadenosine monophosphate. *Mol Pharmacol* 48, 897–904.

Hentosh, P., & Tibudan, M. (1997). 2-Chloro-2'-deoxyadenosine, an anti-leukemic drug, has an early effect on cellular mitochondrial function. *Mol Pharmacol* 51, 613–619.

Hershfield, M. S., Fetter, J. E., Small, W. C., Bagnara, A. S., Williams, S. R., Ullman, B., Martin, D. W., Wasson, D. B., & Carson, D. A. (1982). Effects of mutualional loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxycytidine toxicity in cultured CEM human T-lymphoblastoid cells. *J Biol Chem* 257, 6380–6386.

Herzfeld, A., & Raper, S. M. (1979). Uridine kinase activities in developing, adult and neoplastic rat tissues. *Biochem J* 182, 771–778.

Honkoop, P., Scholte, H. R., de Man, R. A., & Schalm, S. W. (1997). Mitochondrial injury. Lessons from the faluridine trial. *Drug Safety* 17, 1–7.

Huang, P., Sandoval, A., Van Den Neste, E., Keating, M. J., & Plunkett, W. (2000). Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. *Leukemia* 14, 1405–1413.

Hubuscher, U., Nasheuer, H. P., & Syvaoja, J. E. (2000). Eukaryotic DNA polymerases, a growing family. *Trends Biochem Sci* 25, 143–147.

Hurley, M. C., Lin, B., & Fox, I. H. (1985). Regulation of deoxycytosine and nucleoside analog phosphorylation by human placentald adenosine kinase. *J Biol Chem* 260, 15675–15681.

Jansson, O., Bohman, C., Munch-Petersen, B., & Eriksson, S. (1992). Mammalian thymidine kinase 2. Direct photoaffinity labeling with [32P]dTTTP of the enzyme from spleen, liver, heart and brain. *Eur J Biochem* 206, 485–490.

Jarvis, M. F., Yu, H., Kohlhaas, K., Alexander, K., Lee, C. H., Jiang, M., Bhagwat, S. S., Williams, M., & Kowaluk, E. A. (2000). ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido. *Cancer Res* 60, 7258–7262.

Johnson, M., & Karlsson, A. (1996). Localization of the human deoxyguanosine kinase gene (DGUOK) to chromosome 2p13. *Genomics* 38, 450–451.

Johnson, M., Brismar, S., & Karlsson, A. (1997). Human deoxycytidinine kinase is located in the cell nucleus. *Proc Natl Acad Sci USA* 94, 11941–11945.

Johnson, M., Van Rompay, A. R., Degreve, B., Balzarini, J., & Karlsson, A. (1999). Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of *Drosophila melanogaster*. *J Biol Chem* 274, 23814–23819.

Johnson, K., Ramaswamy, S., Ljungcrantz, C., Knecht, W., Piskur, J., Munch-Petersen, B., Eriksson, S., & Eklund, H. (2001). Structural basis for substrate specificities of cellular deoxyribonucleoside kinases. *Nat Struct Biol* 8, 616–620.

Johnson, A. J., Ay, A. S., Hanes, J., Sro, Z., Colacino, M. J., Anderson, K. S., & Johnson, K. A. (2001). Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. *J Biol Chem* 276, 40847–40857.

Johnson, A. J., Mon, A. P., Abhyankar, V., & Byrd, J. C. (2003). Advances in the therapy of chronic lymphocytic leukemia. *Curr Opin Hematol* 10, 297–305.

Jullig, M., & Eriksson, S. (2000). Mitochondrial and submitochondrial localization of human deoxycytosine kinase. *Eur J Biochem* 267, 5466–5472.

Jullig, M., & Eriksson, S. (2001). Apoptosis induces efflux of the mitochondrial matrix enzyme deoxycytosine kinase. *J Biol Chem* 276, 24000–24004.

Kantarjian, H. M., Gandhi, V., Cortes, J., Verstovsek, S., Du, M., Garcia-Manero, G., Giles, F., Faderl, S., O’Brien, S., Jeha, S., Davis, J., Shaked, Z., Craig, A., Keating, M., Plunkett, W., & Freireich, E. J. (2003, June 5). Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemia. *Blood* (Epub ahead of print).

Keating, M. J. (1999). Chronic lymphocytic leukemia. *Semin Oncol* 26, 107–114.

Kim, F. C., Lau, J. S., Rawlings, S., & Lee, A. S. (1997). Positive and negative regulation of the human thymidine kinase promoter mediated by CCAAT binding transcription factors NF-Y/CBF, dbpA, and CDP/cut. *Cell Growth Differ* 8, 1329–1338.

Kit, S., & Leung, W. C. (1974). Submitochondrial localization and characteristcises of thymidine kinase molecular forms in parental and kinase-deficient HeLa cells. *Biochem Genet* 4, 163–168.

Koizumi, K., Shimamoto, Y., Azuma, A., Wataya, Y., Matsuda, A., Sasaki, T., & Fukushima, M. (2001). Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells. *Int J Mol Med* 8, 273–278.

Kornberg, A., & Baker, T. A. (1992). DNA replication. In A. Kornberg, & T. A. Baker (Eds.), *DNA replication (2nd ed.)* (pp. 1–931). New York: W.H. Freeman and Company.

Kovaluk, E. A., Kohlhaas, K. L., Bannon, A., Gunther, K., Lynch, J. J., & Jarvis, M. F. (1999). Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice. *Pharmacol Biochem Behav* 63, 83–91.

Krystal, G., & Scholefield, P. G. (1973). The partial purification and propereties of uridine kinase from Ehrlich ascites tumor cells. *Can J Biochem* 51, 379–389.

Krystal, G., & Webb, T. E. (1971). Multiple forms of uridine kinase in normal and neoplastic rat liver. *Biochem J* 124, 943–947.

Kufe, D., Spriggs, D., Egan, E. M., & Munro, D. (1984). Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. *Blood* 64, 54–58.
Kunkel, T. A., & Bebenek, K. (2000). DNA replication fidelity. Annu Rev Biochem 69, 497–529.

Kuo, W. L., Hirschhorn, R., Huie, M. L., & Hirschhorn, K. (1996). Localization and ordering of acid α-glucosidase (GAA) and thymidine kinase (TK1) by fluorescence in situ hybridization. Hum Genet 97, 404–406.

Lacombe, M. L., Milan, L., Munier, A., Mehus, J. G., & Lambeth, D. O. (2000). The human Nm23-nucleoside diphosphate kinases. J Bioenerg Biomembranes 32, 247–258.

Ladner, R. D. (2001). The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci 2, 361–370.

Lavie, A., Schlichting, I., Vetter, I. R., Konrad, M., Reinstein, J., & Goody, R. S. (1997). The bottleneck in AZT activation. Nat Med 3, 922–924.

Lee, L. S., & Cheng, Y. C. (1976). Human deoxythymidine kinase: I. Molecular cloning. J Biol Chem 251, 1099–1105.

Lindsay, R. H., & Yu, M. W. (1974). Inhibitory effect of 2-thiouracil and 2-thiouracil metabolism on enzymes involved in the pyrimidine nucleoside biosynthesis. Biochem Pharmacol 23, 2273–2281.

Loeb, L. A., & Mullins, J. I. (2000). Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res Hum Retrovir 16, 1–3.

Loeb, L. A., Essignam, J. M., Kazazi, F., Zhang, J., Rose, K. D., & Mullins, J. I. (1999). Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci USA 96, 1492–1497.

Lotti, K., Mánsson, E., Spasokoukotskaja, T., Pettersson, B., Liliemark, J., Peterson, C., Eriksson, S., & Albertioni, F. (1999). Biochemical pharmacology and resistance to 2-chloro-2-arabinofuran-2-deoxyadeno-

Maj, M. C., Singh, B., & Gupta, R. S. (2000). Structure-function studies on mammalian adenosine kinase. Biochem Biophys Res Commun 275, 386–393.

Mancuso, M., Salvati, E., Sacconi, S., Otaegui, D., Camano, P., Marina, A., Bacman, S., Moraes, C. T., Carlo, J. R., Garcia, M., Garcia-Alvarez, M., Monzon, L., Naini, A. B., Hirano, M., Bonilla, E., Taratuto, A. L., & DiMauro, S., & Yu, T. H. (2002). Mitochondrial DNA deletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology 59, 1197–1202.

Mandel, H., Szargel, R., Labay, V., Elpeleg, O., Saada, A., Shalata, A., Anbinder, Y., Berkowitz, D., Hartman, B., Barak, M., Eriksson, S., & Cohen, N. (2001). The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondria DNA. Nat Genet 29, 337–341.

Manfredi, J. P., & Holmes, E. W. (1985). Purine salvage pathways in myocardiun. Annu Rev Physiol 47, 691–705.

Mansson, E., Stridh, H., & Albertioni, F. (2002). Resistance to mitochondrial and- and Fas-mediated apoptosis in human leukemic cells with acquired resistance to 9-\textit{i}-\textit{i}-arabinofuranosylguanosine. Biochem Biophys Res Commun 298, 338–344.

Mansson, E., Fröldal, E., Liliemark, J., Spasokoukotskaja, T., Elford, H., Lagercrantz, S., Eriksson, S., & Albertioni, F. (2003). Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to clara-dinol and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 65, 237–247.

Mansuri, M. M., Starrett Jr., E. J., Ghazouli, I., Hitchcock, M. J., Sterczyk, R. Z., Blankov manufacturing, V., Lin, T. S., August, E. M., Prusoff, W. H., Sommadossi, J. P., & Martin, J. C. (1989). p(2,3-Dideoxy-2-(\textit{R}-glycerophosphate)-2-enofuranosylthymine. A highly potent and selective anti-HIV agent. J Med Chem 32, 461–466.
deoxythymidine (zidovudine) in human mononuclear cells. *Antimicrob Agents Chemother* 35, 198–200.

Taanman, J. W. (1999). The mitochondrial genome: structure, transcription, translation and replication. *Biochim Biophys Acta* 1410, 103–123.

Takatori, S., Kanda, H., Takenaka, K., Wataya, Y., Matsuda, A., Fukushima, M., Shimamoto, Y., Tanaka, M., & Sasaki, T. (1999). Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethyl-β-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethyl-β-D-ribo-pentofuranosyl)uracil. *Cancer Chemother Pharmacol* 44, 97–104.

Tan, X., Chu, C. K., & Boudinot, F. D. (1999). Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationship and pharmacokinetics. *Adv Drug Deliv Rev* 39, 117–151.

Timsit, Y. (1999). DNA structure and polymerase fidelity. *J Mol Biol* 293, 835–838.

Törnøvik, Y., Ullman, B., Balzarini, J., Wahren, B., & Eriksson, S. (1995). Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTTP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM lymphoblastoid cells. *Biochem Pharmacol* 49, 829–837.

Trot, T. W., & Jones, M. E. (1996). Uracil metabolism-UMP synthesis from orotic acid or uridine and conversion of uracil to β-alanine enzymes and cDNAs. *Prog Nucleic Acid Res Mol Biol* 53, 1–78.

Tseng, W. C., Derse, D., Cheng, Y. C., Brockman, R. W., & Bennett Jr., L. L. (1982). In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. *Mol Pharmacol* 21, 474–477.

Turk, B., Awad, R., Usosa, E., Björk, I., & Eriksson, S. (1999). A pre-steady-state kinetic analysis of substrate binding to human recombinant deoxyxycytidine kinase: A model for nucleoside kinase action. *Biochemistry* 38, 8555–8561.

Ugarkar, B. G., Castellino, A. J., DaRe, J. M., Kopcho, J. J., Wiesner, J. B., Ullman, B., Gudas, L. J., Cohen, A., & Martin, D. W. (1978). Deoxyadenosine kinase deficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM lymphoblastoid cells. *Biochem Pharmacol* 49, 829–837.

Van Rompay, A.R. (2001). Identification and characterization of nucleoside and nucleotide kinases: pharmacological activation of anti-cancer and anti-viral nucleoside analogs. PhD thesis. Stockholm: Karolinska Institute.

Van Rompay, A. R., Johansson, M., & Karlsson, A. (1999). Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase; molecular characterization of the human enzyme. *Mol Pharmacol* 56, 562–569.

Van Rompay, A. R., Johansson, M., & Karlsson, A. (2000). Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. *Pharmacol Ther* 87, 189–198.

Van Rompay, A. R., Norda, A., Lindén, K., Johansson, M., & Karlsson, A. (2001). Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. *Mol Pharmacol* 59, 1181–1186.

Verhoeft, V., Sarup, J., & Friland, A. (1981). Identification of the mechanism of activation of 9-β-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases. *Cancer Res* 41, 4478–4483.

Verschuer, A. C., Van Gennip, A. H., Leen, R., Muller, E. J., Elzinga, L., Voute, P. A., & Van Kuijlenburg, A. B. (2000). Cyclopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia: A promising target for chemotherapy. *Eur J Cancer* 36, 627–635.

Vesely, J., & Cihak, A. (1973a). Resistance of mammalian tumor cells toward pyrimidine analogues. A review. *Oncology* 38, 204–226.

Vesely, J., & Cihak, A. (1973b). Uridine kinase in embryonic rat liver: modulation of enzyme activity by 5-aza-cytidine. *Biochem J* 133, 609–613.

Wang, J., & Eriksson, S. (1996). Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. *Antimicrob Agents Chemother* 40, 1555–1557.

Wang, L., & Eriksson, S. (2000). Cloning and characterization of full-length mouse thymidine kinase 2: the N terminal sequence directly imports of the precursor protein into mitochondria. *Biochem J* 351, 469–476.

Wang, L., Karlsson, A., Arne, E. S., & Eriksson, S. J. (1993). Substrate specificity of mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. *J Biol Chem* 268, 22847–22852.

Wang, L., Munch-Petersen, B., Herrstrom Sjöberg, A., Hellman, U., Bergman, T., Jornvall, H., & Eriksson, S. (1999). Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. *FEBS Lett* 443, 170–174.

Waud, W. R., Schmid, S. M., Montgomery, J. A., & Secrist III, J. A. (2000). Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine (CF-ara-A). *Nucleosides Nucleotides Nucleic Acids* 19, 447–460.

Weichsel Jr., M. E., Hoogenraad, N. J., Levine, R. L., & Kretcher, N. (1972). Pyrimidine biosynthesis during development of rat cerebral cortex. *Pediatr Res* 6, 682–686.

Wettin, K., Johansson, M., Zheng, X., Zhu, C., & Karlsson, A. (1999). Cloning of mouse mitochondrial thymidine kinase 2 cDNA. *FEBS Lett* 460, 103–106.

White, J. C., & Hines, L. H. (1987). Role of uridine triphosphate in the phosphorylation of 1-β-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells. *Cancer Res* 47, 1820–1824.

Wiley, J. S., Jones, S. P., Sawyer, W. H., & Paterson, A. R. (1982). Cytosine arabinoside influx and nucleoside transport sites in leukemia. *J Clin Invest* 69, 479–489.

Willis, R. C., Carson, D. A., & Seegmiller, J. E. (1978). Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. *Proc Natl Acad Sci USA* 75, 3042–3044.

Wright, J. A., Chan, A. K., Choy, B. K., Hurla, R. A., McClarty, G. A., & Tagger, A. Y. (1990). Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis. *Biochem Cell Biol* 68, 1364–1371.

Xu, Y. Z., Huang, P., & Plunkett, W. (1995). Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxyxycytidine for DNA repair in human lymphoblasts. *J Biol Chem* 270, 631–637.

Yamada, Y., Goto, H., & Ogasawara, N. (1981). Adenosine kinase from human liver. *Biochim Biophys Acta* 660, 36–43.

Zannis-Hadjopoulos, M., & Price, G. B. (1999). Eukaryotic DNA replication. *J Cell Biochem Suppl* 32–33, 1–14.

Zhu, C. (2000). Deoxyribonucleoside kinases in nuclear and mitochondrial DNA precursor synthesis: Phosphorylation of anti-cancer nucleoside analogs in different subcellular compartments. PhD thesis. Stockholm: Karolinska Institute.

Zhu, C., Johansson, M., Perment, J., & Karlsson, A. (1998a). Phosphorylation of anticancer nucleoside analogs by human mitochondrial deoxyguanosine kinase. *Biochem Pharmacol* 56, 1035–1040.

Zhu, C., Johansson, M., Perment, J., & Karlsson, A. (1998b). Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines. *J Biol Chem* 273, 14707–14711.

Zhu, C., Johansson, M., & Karlsson, A. (2000). Differential incorporation of 1-β-D-arabinofuranosylcytosine and 9-β-D-arabinofuranosylguanine into nuclear and mitochondrial DNA. *FEBS Lett* 474, 129–132.